Ingrid Fricke-Galindo

Author

Instituto Nacional de Enfermedades Respiratorias ORCID

Also Known As

I Fricke-Galindo, I. Fricke Galindo, I. Fricke-Galindo, I.F. Galindo, Ingrid Fricke Galindo, Ingrid Fricke-Galindo

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Instituto Nacional de Enfermedades Respiratorias Universidad Autónoma Metropolitana Universidad Nacional Autónoma de México Instituto Nacional de Neurología y Neurocirugía Universidad Autónoma de Guerrero

About

Ingrid Fricke-Galindo is an author at Instituto Nacional de Enfermedades Respiratorias specializing in medicine, pharmacology, and neurogenetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	129
2	Neurology	2	2	43
3	Epidemiology	1	1	54
4	Genetic Medicine	1	1	13
5	Immunology	1	1	54

Ingrid Fricke-Galindo

Publications

336

Citations

H-Index

Page 1

	Year	Citations
Severe COVID-19 Patients Show an Increase in Soluble TNFR1 and ADAM17, with a Relationship to Mortality Yadira Palacios, Andy Ruíz, Lucero A. Ramón‐Luing, International Journal of Molecular Sciences ImmunodeficienciesImmunologyRenal InflammationPathologyImmune Regulation	2021	54
<i>HLA</i>-<i>A02:01:01</i>/<i>-B35:01:01</i>/<i>-C*04:01:01</i>Haplotype Associated with Lamotrigine-Induced Maculopapular Exanthema in Mexican Mestizo Patients Ingrid Fricke-Galindo, Iris E. Martínez‐Juárez, Nancy Monroy‐Jaramillo, Pharmacogenomics	2014	49
Interethnic Variability in <i>CYP2D6</i> , <i>CYP2C9</i> , and <i>CYP2C19</i> Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics María-Eugenia G. Naranjo, Fernanda Rodrigues‐Soares, Eva Peñas‐Lledó, OMICS A Journal of Integrative Biology	2018	48
IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19 Ingrid Fricke-Galindo, Alfonso Martínez-Morales, Leslie Chávez‐Galán, Frontiers in Immunology	2022	47
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy Alberto Ortega‐Vázquez, Pedro Dorado, Ingrid Fricke-Galindo, The Pharmacogenomics Journal Plasma ConcentrationsMolecular PharmacologyMexican-mestizo PatientsGeneticsMedicine	2015	30
Outcome predictors in COVID-19: An analysis of emergent systemic inflammation indices in Mexican population Ilse Adriana Gutiérrez-Pérez, Ivette Buendía-Roldán, Gloría Pérez-Rubio, Frontiers in Medicine	2022	24
SERPINE1 rs6092 Variant Is Related to Plasma Coagulation Proteins in Patients with Severe COVID-19 from a Tertiary Care Hospital Ingrid Fricke-Galindo, Ivette Buendía-Roldán, Leslie Chávez‐Galán, Biology ThrombosisTertiary Care HospitalFactor IxSerpine1 Rs6092 VariantViral Diagnostics	2022	19
<i>TNFRSF1B</i> and <i>TNF</i> Variants Are Associated With Differences in Levels of Soluble Tumor Necrosis Factor Receptors in Patients With Severe COVID-19 Ingrid Fricke-Galindo, Ivette Buendía-Roldán, Andy Ruíz, The Journal of Infectious Diseases	2022	17
Allele and Genotype Frequencies of Genes Relevant to Anti-Epileptic Drug Therapy in Mexican-Mestizo Healthy Volunteers Ingrid Fricke-Galindo, Alberto Ortega‐Vázquez, Nancy Monroy‐Jaramillo, Pharmacogenomics GeneticsGenetic EpidemiologyHuman PolymorphismPharmacotherapyGenetic Medicine	2016	13
Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy Alberto Ortega‐Vázquez, Ingrid Fricke-Galindo, Pedro Dorado, The Pharmacogenomics Journal Genetic VariantsAntiepileptic Drug Co-treatmentPharmacologyLamotrigine Plasma ConcentrationNeurology	2020	13

Page 1